Clinical trial · Interventional
RCT on Adjuvant TACE After Hepatectomy for HCC
Randomised Controlled Trial on Adjuvant Transarterial Chemoembolisation After Curative Hepatectomy for Hepatocellular Carcinoma
NCT01512407CI-TRIAL-00057211A-TECHcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival. The aim of this study is to compare the survival of patients undergoing liver resection plus post-operative TACE versus liver resection alone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transarterial chemoembolisation using cisplatin-lipiodol mixture | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Hepatectomy plus TACE
- description
- Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
- interventionNames
- Procedure: Transarterial chemoembolisation using cisplatin-lipiodol mixture
- type
- NO_INTERVENTION
- label
- Hepatectomy alone
Primary outcomes (1)
- measure
- 1-year recurrence rate
- timeFrame
- 1-year after hepatectomy
- description
- The 1-year recurrence rate after hepatectomy in both arms of study were compared
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * HCC patients received curative hepatectomy with negative resection margin * Age from 18 to 70 * Child-Pugh class A * ASA class I to III * ECOG performance status Grade 0 or 1 Exclusion Criteria: * Patients receiving concomitant local ablation or previous TACE * Main portal vein tumour thrombus extraction during hepatectomy * Tumour arising from caudate lobe * Presence of extra-hepatic disease * Very early HCC with solitary tumour and size \< 2cm * Impaired liver function with either clinically detected ascites, hepatic encephalopathy, serum albumin \< 25g/L or bilirubin \> 50micromol/L * Renal impairment with creatinine \> 200micromol/L * Severe concurrent medical illness persisting \> 6 weeks after hepatectomy * History of other cancer * Hepatic artery anomaly making TACE not possible * Allergy to cisplatin or lipiodol * Pregnant woman * Informed consent not available
References
Publications (0)
Data not yet available
No reference posted for this study.